Tag: discordance

Articles

• Hormone receptor and HER2 status changes can influence prognosis

News

10/07/20

Differences in HER2 expression between tumors affects outcomes

07/20/14

HER2 status of lymph nodes can differ from that of primary tumor

12/02/11

Knowing receptor status of metastases improves treatment decisions

Studies

• HER2 status results in an unstable switch from primary to recurrent breast cancer Cite
  Zhu A, Wang N, Yun Z, Liu X, Liang X, Yan Y, et al. HER2 status results in an unstable switch from primary to recurrent breast cancer. Neoplasma. AEPress, s.r.o.; 2024; 71:392-401 10.4149/neo_2024_240229n89
• Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance Cite
  Van Bockstal MR, Wesseling J, Lips EH, Smidt M, Galant C, van Deurzen CHM. Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance. Breast Cancer Research. Springer Science and Business Media LLC; 2024; 26 10.1186/s13058-024-01875-w
• Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease Cite
  Dowling GP, Keelan S, Cosgrove NS, Daly GR, Giblin K, Toomey S, et al. Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07431-6
• A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression Cite
  Boman C, Liu X, Eriksson Bergman L, Sun W, Tranchell C, Toli MA, et al. A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression. British Journal of Cancer. Springer Science and Business Media LLC; 2024; 10.1038/s41416-024-02777-6
• Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer Cite
  Kutlu Y, Cekin R, Aydin SG, Shbair ATM, Bilici A, Arici S, et al. Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer. Current Problems in Cancer. Elsevier BV; 2024; 50:101102 10.1016/j.currproblcancer.2024.101102
• Discordance of HER2-low Status between Breast Primary and Distant Metastases with Clinical-pathological Correlation Cite
  Yang E, D’Alfonso T, Morrow M, Brogi E, Wen H. Discordance of HER2-low Status between Breast Primary and Distant Metastases with Clinical-pathological Correlation. Research Square Platform LLC; 2024; 10.21203/rs.3.rs-4284023/v1
• Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status Cite
  Na S, Kim M, Park Y, Kwon HJ, Shin H, Kim E, et al. Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status. Breast Cancer. Springer Science and Business Media LLC; 2024; 10.1007/s12282-024-01585-3
• Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study Cite
  Morganti S, Marra A, Gandini S, Ascione L, Ivanova M, Venetis K, et al. Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study. European Journal of Cancer. Elsevier BV; 2023; 195:113397 10.1016/j.ejca.2023.113397
• Tumor Characteristics of Bilateral Breast Cancer Compared with Unilateral Breast Cancer Cite
  Schulze AK, Hoskin TL, Moldoveanu D, Sturz JL, Boughey JC. Tumor Characteristics of Bilateral Breast Cancer Compared with Unilateral Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-14451-x
• Frequency of genetic alterations differs in advanced breast cancer between metastatic sites Cite
  Grote I, Poppe A, Lehmann U, Christgen M, Kreipe H, Bartels S. Frequency of genetic alterations differs in advanced breast cancer between metastatic sites. Genes, Chromosomes and Cancer. Wiley; 2023; 10.1002/gcc.23199
• Carvacrol-Fabricated Chitosan Nanoparticle Synergistic Potential with Topoisomerase Inhibitors on Breast and Cervical Cancer Cells Cite
  Akhlaq A, Ashraf M, Omer MO, Altaf I. Carvacrol-Fabricated Chitosan Nanoparticle Synergistic Potential with Topoisomerase Inhibitors on Breast and Cervical Cancer Cells. ACS Omega. American Chemical Society (ACS); 2023; 10.1021/acsomega.3c03337
• Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases Cite
  Zhu S, Lu Y, Fei X, Shen K, Chen X. Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases. British Journal of Cancer. Springer Science and Business Media LLC; 2023; 10.1038/s41416-023-02403-x
• The dynamics of HER2-low expression during breast cancer progression Cite
  Anderson S, Bartow BB, Siegal GP, Huang X, Wei S. The dynamics of HER2-low expression during breast cancer progression. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07020-z
• Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers Cite
  Bergeron A, Bertaut A, Beltjens F, Charon-Barra C, Amet A, Jankowski C, et al. Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers. British Journal of Cancer. Springer Science and Business Media LLC; 2023; 129:122-134 10.1038/s41416-023-02287-x
• Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy Cite
  Vemuru S, Huang J, Colborn K, Yoon Y, Huynh V, Leonard L, et al. Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-06978-0
• Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients Cite
  Bo J, Yu B, Bi R, Xu X, Cheng Y, Tu X, et al. Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients. Clinical Breast Cancer. Elsevier BV; 2023; 10.1016/j.clbc.2023.03.002
• Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases Cite
  Trillo P, Sandoval J, Trapani D, Nicolò E, Zagami P, Giugliano F, et al. Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases. European Journal of Cancer. Elsevier BV; 2023; 185:119-130 10.1016/j.ejca.2023.02.028
• Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy Cite
  Ma Y, Zhu M, Lv M, Yuan P, Chen X, Liu Z. Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy. Cancer Medicine. Wiley; 2023; 10.1002/cam4.5839
• Evolution of biological features of invasive lobular breast cancer: comparison between primary tumor and metastases Cite
  Aliaga PT, Sandoval J, Trapani D, Nicolò E, Zagami P, Giugliano F, et al. Evolution of biological features of invasive lobular breast cancer: comparison between primary tumor and metastases. European Journal of Cancer. Elsevier BV; 2023; 10.1016/j.ejca.2023.02.028
• Abstract P3-05-08: Prevalence and prognosis of ER-loss in advanced invasive lobular carcinoma Cite
  Hensing WL, Xiu J, Korn WM, Graff SL, Kang I, Torres ETR, et al. Abstract P3-05-08: Prevalence and prognosis of ER-loss in advanced invasive lobular carcinoma. Cancer Research. American Association for Cancer Research (AACR); 2023; 83:P3-05-08-P3-05-08 10.1158/1538-7445.sabcs22-p3-05-08
• Discordance of HER2-low between primary tumors and matched distant metastases in breast cancer Cite
  Almstedt K, Krauthauser L, Kappenberg F, Wagner D, Heimes A, Battista MJ, et al. Discordance of HER2-low between primary tumors and matched distant metastases in breast cancer. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-2478913/v1
• Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls Cite
  Morganti S, Ivanova M, Ferraro E, Ascione L, Vivanet G, Bonizzi G, et al. Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls. Cancer Drug Resistance. OAE Publishing Inc.; 2022; 5:971-80 10.20517/cdr.2022.55
• Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases Cite
  Lin M, Jin Y, Lv H, Hu X, Zhang J. Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. International Journal of Cancer. Wiley; 2022; 10.1002/ijc.34365
• Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis Cite
  Rothé F, Venet D, Peeters D, Rouas G, Rediti M, Smeets D, et al. Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis. npj Breast Cancer. Springer Science and Business Media LLC; 2022; 8 10.1038/s41523-022-00445-7
• Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer Cite
  Lips EH, Kumar T, Megalios A, Visser LL, Sheinman M, Fortunato A, et al. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Nature Genetics. Springer Science and Business Media LLC; 2022; 54:850-860 10.1038/s41588-022-01082-3
• Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy Cite
  Zhou H, Yu J, Wang X, Shen K, Ye J, Chen X. Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy. Scientific Reports. Springer Science and Business Media LLC; 2022; 12 10.1038/s41598-022-06206-7
• The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry Cite
  Meegdes M, Ibragimova KIE, Lobbezoo DJA, Vriens IJH, Kooreman LFS, Erdkamp FLG, et al. The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-021-06472-5
• Predictive and prognostic significance of BRCAness in HER2-negative breast cancer Cite
  Sueta A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, Goto-Yamaguchi L, Iwase H, et al. Predictive and prognostic significance of BRCAness in HER2-negative breast cancer. Breast Cancer. Springer Science and Business Media LLC; 2022; 10.1007/s12282-021-01319-9
• Evolution of HER2-low expression from primary to recurrent breast cancer Cite
  Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-021-00343-4
• Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes Cite
  Wetzel CL, Sutton TL, Gardiner S, Farinola M, Johnson N, Garreau JR. Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes. Journal of Surgical Oncology. Wiley; 2021; 10.1002/jso.26646
• The rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant Tamoxifen administration Cite
  Djahansouzi S, Hanstein B, Rein D, Clees M, Rath W. The rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant Tamoxifen administration. Cancer Reports. Wiley; 2021; 10.1002/cnr2.1431
• HER2 receptor conversion is a strong survival predictor in patients with breast cancer brain metastases Cite
  Michel A, Oppong MD, Rauschenbach L, Pierscianek D, Dinger TF, Schmidt T, et al. HER2 receptor conversion is a strong survival predictor in patients with breast cancer brain metastases. World Neurosurgery. Elsevier BV; 2021; 10.1016/j.wneu.2021.05.096
• Using dynamic cell communication improves treatment strategies of breast cancer Cite
  Liu Z, Hu S, Yun Z, Hu W, Zhang S, Luo D. Using dynamic cell communication improves treatment strategies of breast cancer. Cancer Cell International. Springer Science and Business Media LLC; 2021; 21 10.1186/s12935-021-01979-9
• Prognostic significance of estrogen, progesterone and HER2 receptors’ status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia Cite
  Al-Saleh K, Salah T, Arafah M, Husain S, Al-Rikabi A, Abd El-Aziz N. Prognostic significance of estrogen, progesterone and HER2 receptors’ status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia. PLOS ONE. Public Library of Science (PLoS); 2021; 16:e0247802 10.1371/journal.pone.0247802
• Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer Cite
  Katayama A, Miligy IM, Shiino S, Toss MS, Eldib K, Kurozumi S, et al. Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. Modern Pathology. Springer Science and Business Media LLC; 2021; 10.1038/s41379-021-00738-5
• Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer Cite
  Van Raemdonck E, Floris G, Berteloot P, Laenen A, Vergote I, Wildiers H, et al. Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05935-5
• Receptor discordance and phenotype change in metastatic breast cancer Cite
  Kao J, Tsai J, Wu T, Wang C, Kuo Y. Receptor discordance and phenotype change in metastatic breast cancer. Asian Journal of Surgery. Elsevier BV; 2020; 10.1016/j.asjsur.2020.05.032
• Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer Cite
  Walter V, Fischer C, Deutsch TM, Ersing C, Nees J, Schütz F, et al. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 183:137-144 10.1007/s10549-020-05746-8
• Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT Cite
  Ulaner GA, Carrasquillo JA, Riedl CC, Yeh R, Hatzoglou V, Ross DS, et al. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT. Radiology. Radiological Society of North America (RSNA); 2020; 296:370-378 10.1148/radiol.2020192828
• Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer Cite
  Ding Y, Ding K, Qian H, Yu X, Zou D, Yang H, et al. Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer. PLOS ONE. Public Library of Science (PLoS); 2020; 15:e0231895 10.1371/journal.pone.0231895
• The effect of smoking on biological change of recurrent breast cancer Cite
  Takada K, Kashiwagi S, Asano Y, Goto W, Kouhashi R, Yabumoto A, et al. The effect of smoking on biological change of recurrent breast cancer. Research Square; 2020; 10.21203/rs.2.23974/v1
• Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy Cite
  Rossi L, Verrico M, Tomao S, Ricci F, Fontana A, Spinelli GP, et al. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy. Cancer Chemotherapy and Pharmacology. Springer Science and Business Media LLC; 2019; 85:105-111 10.1007/s00280-019-03981-5
• Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample Cite
  Zhu S, Wu J, Huang O, He J, Zhu L, Li Y, et al. Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 26:2779-2786 10.1245/s10434-019-07480-y
• The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer Cite
  VOGEL C, MALTER W, MORGENSTERN B, LUDWIG S, VEHRESCHILD JJ, HAMACHER S, et al. The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer. Anticancer Research. Anticancer Research USA Inc.; 2019; 39:2647-2659 10.21873/anticanres.13389
• When breast cancer gets complicated. A case report of synchronous bilateral breast cancers with discordant tumor markers from the primary to nodes with findings of a sentinel internal mammary subpectoral lymph node Cite
  Brock CM, Clippard L. When breast cancer gets complicated. A case report of synchronous bilateral breast cancers with discordant tumor markers from the primary to nodes with findings of a sentinel internal mammary subpectoral lymph node. Journal of Surgical Case Reports. Oxford University Press (OUP); 2019; 2019 10.1093/jscr/rjz015
• Loss of HER2 after HER2-targeted treatment Cite
  Ignatov T, Gorbunow F, Eggemann H, Ortmann O, Ignatov A. Loss of HER2 after HER2-targeted treatment. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 175:401-408 10.1007/s10549-019-05173-4
• Does Breast Tumor Heterogeneity Necessitate Further Immunohistochemical Staining on Surgical Specimens? Cite
  Greer LT, Rosman M, Mylander WC, Hooke J, Kovatich A, Sawyer K, et al. Does Breast Tumor Heterogeneity Necessitate Further Immunohistochemical Staining on Surgical Specimens?. Journal of the American College of Surgeons. Elsevier BV; 2013; 216:239-251 10.1016/j.jamcollsurg.2012.09.007
• Role of rebiopsy in metastatic breast cancer at progression Cite
  Sharma M, Gogia A, Deo SS, Mathur S. Role of rebiopsy in metastatic breast cancer at progression. Current Problems in Cancer. Elsevier BV; 2019; 43:438-442 10.1016/j.currproblcancer.2018.12.001
• Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies Cite
  Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, et al. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies. Nature Genetics. Springer Science and Business Media LLC; 2018; 51:207-216 10.1038/s41588-018-0287-5
• Discordance in Hormone Receptor Status of Primary Versus Metastatic Breast Carcinoma Cite
  Manrai P, Partovi E, Lo Y, Darbinyan A, Pinto M, Kowalski D, et al. Discordance in Hormone Receptor Status of Primary Versus Metastatic Breast Carcinoma. Journal of the American Society of Cytopathology. Elsevier BV; 2018; 7:S4-S5 10.1016/j.jasc.2018.06.023
• Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? Cite
  De La Cruz LM, Harhay MO, Zhang P, Ugras S. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2018; 25:3535-3540 10.1245/s10434-018-6608-1
• Loss of HER2 amplification and disease prognosis after neoadjuvant treatment of HER2 amplified breast cancer Cite
  Paralta Branco F, Silva F, André S, Catarino A, Madureira R, Moreira Pinto J, et al. Loss of HER2 amplification and disease prognosis after neoadjuvant treatment of HER2 amplified breast cancer. European Journal of Cancer. Elsevier BV; 2018; 92:S94 10.1016/s0959-8049(18)30510-0
• Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options Cite
  McAnena PF, McGuire A, Ramli A, Curran C, Malone C, McLaughlin R, et al. Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4101-7
• Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer Cite
  Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, van't Veer LJ, et al. Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2018; 110:726-733 10.1093/jnci/djx270
• Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis Cite
  Schrijver WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, Moelans CB, van Diest PJ. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2018; 110:568-580 10.1093/jnci/djx273
• Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study Cite
  Kaidar-Person O, Meattini I, Jain P, Bult P, Simone N, Kindts I, et al. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 167:479-483 10.1007/s10549-017-4526-8
• Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer Cite
  De Gregorio A, Friedl TW, Huober J, Scholz C, De Gregorio N, Rack B, et al. Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. JCO Precision Oncology. American Society of Clinical Oncology (ASCO); 2017;:1-12 10.1200/po.17.00023
• Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer Cite
  Yoshida A, Hayashi N, Suzuki K, Takimoto M, Nakamura S, Yamauchi H. Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer. Journal of Surgical Oncology. Wiley; 2017; 116:1021-1028 10.1002/jso.24762
• Abstract P1-01-09: Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients Cite
  Aktas B, Westerwick D, Mairinger F, Kasimir-Bauer S, Kimmig R, Schmid K, et al. Abstract P1-01-09: Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p1-01-09
• HER2 expression identifies dynamic functional states within circulating breast cancer cells Cite
  Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. Springer Science and Business Media LLC; 2016; 537:102-106 10.1038/nature19328
• Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients Cite
  Zhang S, Li L, Wang T, Bian L, Hu H, Xu C, et al. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2578-5
• Discordance Between Intraoperative Consultation by Frozen Section and Final Diagnosis Cite
  Sams SB, Wisell JA. Discordance Between Intraoperative Consultation by Frozen Section and Final Diagnosis. International Journal of Surgical Pathology. SAGE Publications; 2016; 25:41-50 10.1177/1066896916662152
• Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a review Cite
  Yeung C, Hilton J, Clemons M, Mazzarello S, Hutton B, Haggar F, et al. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a review. Cancer and Metastasis Reviews. Springer Science and Business Media LLC; 2016; 35:427-437 10.1007/s10555-016-9631-3
• Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification Cite
  Allott EH, Geradts J, Sun X, Cohen SM, Zirpoli GR, Khoury T, et al. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification. Breast Cancer Research. Springer Science and Business Media LLC; 2016; 18 10.1186/s13058-016-0725-1
• Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer Cite
  Shiino S, Kinoshita T, Yoshida M, Jimbo K, Asaga S, Takayama S, et al. Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2016; 16:e133-e140 10.1016/j.clbc.2016.05.014
• Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression – Implications for the practising oncologist Cite
  Gahlaut R, Bennett A, Fatayer H, Dall BJ, Sharma N, Velikova G, et al. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression – Implications for the practising oncologist. European Journal of Cancer. Elsevier BV; 2016; 60:40-48 10.1016/j.ejca.2016.03.006
• Abstract P2-02-02: Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer Cite
  Janni W, Schramm A, Friedl T, Schochter F, Huober J, Rack B, et al. Abstract P2-02-02: Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p2-02-02
• Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes Cite
  Thomson AH, McGrane J, Mathew J, Palmer J, Hilton DA, Purvis G, et al. Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes. British Journal of Cancer. Springer Science and Business Media LLC; 2016; 114:793-800 10.1038/bjc.2016.34
• The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy? Cite
  Sun Y, Liu X, Cui S, Li L, Tian P, Liu S, et al. The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy?. Tumor Biology. Springer Science and Business Media LLC; 2016; 37:9555-9563 10.1007/s13277-016-4844-1
• Reliability of Prognostic and Predictive Factors Evaluated by Needle Core Biopsies of Large Breast Invasive Tumors Cite
  Petrau C, Clatot F, Cornic M, Berghian A, Veresezan L, Callonnec F, et al. Reliability of Prognostic and Predictive Factors Evaluated by Needle Core Biopsies of Large Breast Invasive Tumors. American Journal of Clinical Pathology. Oxford University Press (OUP); 2015; 144:555-562 10.1309/ajcp9kfvm2gzmndv
• Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors Cite
  Nakamura R, Yamamoto N, Shiina N, Miyaki T, Ikebe D, Itami M, et al. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors. The Breast. Elsevier BV; 2016; 26:141-147 10.1016/j.breast.2015.10.009
• Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry Cite
  Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry. Annals of Oncology. Elsevier BV; 2016; 27:480-487 10.1093/annonc/mdv611
• Utility of Estrogen Receptor, Progesterone Receptor, and HER-2/neuAnalysis of Multiple Foci in Multifocal Ipsilateral Invasive Breast Carcinoma Cite
  East EG, Pang JC, Kidwell KM, Jorns JM. Utility of Estrogen Receptor, Progesterone Receptor, and HER-2/neuAnalysis of Multiple Foci in Multifocal Ipsilateral Invasive Breast Carcinoma. American Journal of Clinical Pathology. Oxford University Press (OUP); 2015; 144:952-959 10.1309/ajcpfwxp54olilmu
• Prognostic value of receptor status change following neoadjuvant chemotherapy in locally advanced breast cancer Cite
  Ozmen V, Atasoy A, Bozdogan A, Dincer M, Eralp Y, Tuzlali S. Prognostic value of receptor status change following neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Treatment Communications. Elsevier BV; 2015; 4:89-95 10.1016/j.ctrc.2015.07.001
• Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer Cite
  Rocca A, Farolfi A, Maltoni R, Carretta E, Melegari E, Ferrario C, et al. Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 152:57-65 10.1007/s10549-015-3423-2
• Abstract P2-04-05: Modeling luminal breast cancer heterogeneity: Combination therapies to suppress hormone receptor-negative subpopulations among receptor-positive ones Cite
  Scaling AL, Knox AJ, Pinto MP, Bliesner BS, Haughian JM, Abdel-Hafiz HA, et al. Abstract P2-04-05: Modeling luminal breast cancer heterogeneity: Combination therapies to suppress hormone receptor-negative subpopulations among receptor-positive ones. Poster Session Abstracts. American Association for Cancer Research; 2015; 10.1158/1538-7445.sabcs14-p2-04-05
• Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease Cite
  Rossi S, Basso M, Strippoli A, Dadduzio V, Cerchiaro E, Barile R, et al. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease. Clinical Breast Cancer. Elsevier BV; 2015; 15:307-312 10.1016/j.clbc.2015.03.010
• Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence Cite
  Okumura Y, Nishimura R, Nakatsukasa K, Yoshida A, Masuda N, Tanabe M, et al. Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2015; 41:548-552 10.1016/j.ejso.2015.01.030
• Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes Cite
  Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, et al. Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clinical Breast Cancer. Elsevier BV; 2015; 15:153-160 10.1016/j.clbc.2014.09.006
• Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation Cite
  Tuccari G, Ieni A, Barresi V, Caltabiano R, Zeppa P, Del Sordo R, et al. Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation. OncoTargets and Therapy. Informa UK Limited; 2014;:1267 10.2147/ott.s65294
• Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer Cite
  Kaufman PA, Bloom KJ, Burris H, Gralow JR, Mayer M, Pegram M, et al. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer. Cancer. Wiley; 2014; 120:2657-2664 10.1002/cncr.28710
• Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient Cite
  Hoefnagel L, van der Groep P, van de Vijver M, Boers J, Wesseling P, Wesseling J, et al. Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. Annals of Oncology. Elsevier BV; 2013; 24:3017-3023 10.1093/annonc/mdt390
• Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer Cite
  Yang Y, Liao Y, Li L, Xie S, Xie Y, Peng N. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer. Pathology - Research and Practice. Elsevier BV; 2013; 209:797-802 10.1016/j.prp.2013.08.012
• Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Cite
  Babayan A, Hannemann J, Spötter J, Müller V, Pantel K, Joosse SA. Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e75038 10.1371/journal.pone.0075038
• Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis Cite
  Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, Villanueva C, et al. Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis. The Oncologist. Wiley; 2013; 18:667-674 10.1634/theoncologist.2012-0350
• Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer Cite
  Krishnamurthy S, Bischoff F, Ann Mayer J, Wong K, Pham T, Kuerer H, et al. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. Cancer Medicine. Wiley; 2013; 2:226-233 10.1002/cam4.70
• Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status Cite
  Simonsson M, Söderlind V, Henningson M, Hjertberg M, Rose C, Ingvar C, et al. Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status. Cancer Causes & Control. Springer Science and Business Media LLC; 2013; 24:929-940 10.1007/s10552-013-0169-1
• Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status Cite
  Penault-Llorca F, Coudry RA, Hanna WM, Osamura RY, Rüschoff J, Viale G. Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status. The Breast. Elsevier BV; 2013; 22:200-202 10.1016/j.breast.2012.12.004
• Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer Cite
  Aurilio G, Monfardini L, Rizzo S, Sciandivasci A, Preda L, Bagnardi V, et al. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncologica. Informa UK Limited; 2013; 52:1649-1656 10.3109/0284186x.2012.754990
• HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics Cite
  Ataseven B, Gologan D, Gunesch A, Kehl V, Hoegel B, Beer M, et al. HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics. Breast Care. S. Karger AG; 2012; 7:465-470 10.1159/000345467
• Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact Cite
  Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, et al. Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact. Oncology. S. Karger AG; 2013; 84:150-157 10.1159/000345795
• A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease Cite
  Chan A, Morey A, Brown B, Hastrich D, Willsher P, Ingram D. A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease. BMC Cancer. Springer Science and Business Media LLC; 2012; 12 10.1186/1471-2407-12-555
• Estrogen Receptor Status in Relation to Risk of Contralateral Breast Cancer–A Population-Based Cohort Study Cite
  Sandberg MEC, Hall P, Hartman M, Johansson ALV, Eloranta S, Ploner A, et al. Estrogen Receptor Status in Relation to Risk of Contralateral Breast Cancer–A Population-Based Cohort Study. PLoS ONE. Public Library of Science (PLoS); 2012; 7:e46535 10.1371/journal.pone.0046535
• Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis Cite
  Dieci M, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis. Annals of Oncology. Elsevier BV; 2013; 24:101-108 10.1093/annonc/mds248
• Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer Cite
  Sandberg MEC, Hartman M, Klevebring D, Eloranta S, Ploner A, Hall P, et al. Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 134:793-800 10.1007/s10549-012-2096-3
• Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases Cite
  Hoefnagel LDC, Moelans CB, Meijer SL, van Slooten H, Wesseling P, Wesseling J, et al. Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer. Wiley; 2012; 118:4929-4935 10.1002/cncr.27518
• Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies Cite
  Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, et al. Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treatment Reviews. Elsevier BV; 2012; 38:708-714 10.1016/j.ctrv.2011.11.006
• Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study Cite
  Cronin-Fenton DP, Hellberg Y, Lauridsen KL, Ahern TP, Garne JP, Rosenberg C, et al. Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study. Acta Oncologica. Informa UK Limited; 2011; 51:254-261 10.3109/0284186x.2011.633556
• Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer Cite
  Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, et al. Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:587-592 10.1200/jco.2010.33.5232
• Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression Cite
  Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:2601-2608 10.1200/jco.2011.37.2482
• Concordance in histological and biological parameters between first and second primary breast cancers Cite
  Huo D, Melkonian S, Rathouz PJ, Khramtsov A, Olopade OI. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer. Wiley; 2010; 117:907-915 10.1002/cncr.25587
• Stability of estrogen receptor status in breast carcinoma Cite
  Gong Y, Han EY, Guo M, Pusztai L, Sneige N. Stability of estrogen receptor status in breast carcinoma. Cancer. Wiley; 2010; 117:705-713 10.1002/cncr.25506
• Discordance in hormone receptor status in breast cancer during tumor progression. Cite
  Karlsson E, Lindström LS, Wilking U, Skoog L, Johansson U, Bergh J. Discordance in hormone receptor status in breast cancer during tumor progression.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1009-1009 10.1200/jco.2010.28.15_suppl.1009
• Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases Cite
  Aitken S, Thomas J, Langdon S, Harrison D, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Annals of Oncology. Elsevier BV; 2010; 21:1254-1261 10.1093/annonc/mdp427